Neratinib in HER2-Positive Breast Cancer Patients
Rutugandha Paranjpe(Merck & Co., Inc., Rahway, NJ, USA (United States)), Meghana V. Trivedi(University of Houston), Ekim Ekinci(Houston Methodist), Gabriel Tao(University of Houston), Sobia Noormohammed(University of Houston), Susan Abughosh(University of Houston), Romi Ghose(University of Houston), Dima Basatneh(University of Houston), Carmine De Angelis(Baylor College of Medicine)
Cited by 30
Related Papers
Metastasis Dormancy in Estrogen Receptor–Positive Breast Cancer
|Clinical Cancer Research|2013|273
Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to Metastasize
|Cancer Research|2018|221
Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications
|Breast Care|2013|200
FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer
|Proceedings of the National Academy of Sciences|2016|185
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade
|JNCI Journal of the National Cancer Institute|2019|168